Добірка наукової літератури з теми "Immunosuppressive agents Economic aspects"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Immunosuppressive agents Economic aspects".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Immunosuppressive agents Economic aspects"
Grbovic, Leposava, and Miroslav Radenkovic. "Therapeutic use of glucocorticoids and immunosuppressive agents." Srpski arhiv za celokupno lekarstvo 133, Suppl. 1 (2005): 67–73. http://dx.doi.org/10.2298/sarh05s1067g.
Повний текст джерелаStübgen, Joerg-Patrick. "Biological Agents for Chronic Inflammatory Demyelinating Polyradiculoneuropathy." US Neurology 10, no. 01 (2014): 38. http://dx.doi.org/10.17925/usn.2014.10.01.38.
Повний текст джерелаStübgen, Joerg-Patrick. "Biological Agents for Chronic Inflammatory Demyelinating Polyradiculoneuropathy." European Neurological Review 8, no. 1 (2012): 57. http://dx.doi.org/10.17925/enr.2013.08.01.57.
Повний текст джерелаShabanova, M. "Sociostructural Aspects of Socio-Economic Development:The role of Economic approach." Voprosy Ekonomiki, no. 3 (March 20, 2014): 86–105. http://dx.doi.org/10.32609/0042-8736-2014-3-86-105.
Повний текст джерелаRеsаnоvic, Rаdmilа. "Clinical aspects of immunosuppression in poultry." Veterinarski glasnik 69, no. 1-2 (2015): 91–99. http://dx.doi.org/10.2298/vetgl1502091r.
Повний текст джерелаShamsutdinova, Marina, Nadezhda Zhilina, and Vladimir Ignatiev. "Methodological aspects of assessing the social capital of economic agents." Russian Journal of Management 7, no. 4 (January 28, 2020): 166–70. http://dx.doi.org/10.29039/2409-6024-2019-7-4-166-170.
Повний текст джерелаGorce, Philippe, and Jean-Louis Pourriat. "(Part 1) Economic aspects of concentration-oriented anaesthesia: intravenous agents." Best Practice & Research Clinical Anaesthesiology 15, no. 1 (March 2001): 137–42. http://dx.doi.org/10.1053/bean.2001.0141.
Повний текст джерелаFeiss, Pierre. "(Part 2) Economic aspects of concentration-oriented anaesthesia: halogenated agents." Best Practice & Research Clinical Anaesthesiology 15, no. 1 (March 2001): 143–53. http://dx.doi.org/10.1053/bean.2001.0142.
Повний текст джерелаSnowsill, Tristan M., Jason Moore, Ruben E. Mujica Mota, Jaime L. Peters, Tracey L. Jones-Hughes, Nicola J. Huxley, Helen F. Coelho, et al. "Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation." Nephrology Dialysis Transplantation 32, no. 7 (June 1, 2017): 1251–59. http://dx.doi.org/10.1093/ndt/gfx074.
Повний текст джерелаBauer, Andrea C., Rodrigo F. Franco, and Roberto C. Manfro. "Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols." Current Pharmaceutical Design 26, no. 28 (August 31, 2020): 3440–50. http://dx.doi.org/10.2174/1381612826666200521142448.
Повний текст джерелаДисертації з теми "Immunosuppressive agents Economic aspects"
Jones, Terence Edward. "Economically beneficial drug interactions with cyclosporin and tacroliumus : clinical studies in recipients of kidney and liver transplants." Title page, contents and abstract only, 2000. http://web4.library.adelaide.edu.au/theses/09PH/09phj79.pdf.
Повний текст джерелаPattison, James Michael. "Aspects of the function and regulation of the human chemokine RANTES." Thesis, University of Oxford, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308849.
Повний текст джерелаGuo, Hong, and 郭紅. "Effects of anti-DNA antibodies on pleural mesothelial cells: in vitro studies to explore thepathogenetic mechanism of pulmonary lupus." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B26631945.
Повний текст джерелаpublished_or_final_version
abstract
toc
Medicine
Master
Master of Philosophy
Tai, Lin-hay, and 戴連喜. "Competitiveness and survival of Hong Kong real estate agencies." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B3125682X.
Повний текст джерела莊崇秉 and Shung-ping Charles Chong. "A new era for the Hong Kong real estate agency industry." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B31256788.
Повний текст джерелаKhong, Andrea. "Effect of murine cytomegalovirus infection on haematopoiesis and myeloid cell differentiation and function." University of Western Australia. School of Biomedical, Biomolecular and Chemical Sciences, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0260.
Повний текст джерелаPohlmann, Corinne. "The restructuring of the Montreal tourism industry : a sectoral analysis." Thesis, McGill University, 1994. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=26310.
Повний текст джерелаI begin with an overview of past attempts to understand the changing role of the service sector in developed economies. Despite their weaknesses new political economy frameworks are shown to perhaps provide the best starting point for the development of a more 'services informed' approach to understanding current economic change.
In an attempt to highlight the strengths and weaknesses of applying such approaches to the study of services I first review their ability to explain and predict changes currently taking place in the tourism industry as a whole. This is followed by a discussion of the empirical findings of the thesis based on 103 interviews with managers and owners of Montreal hotels and travel agencies. I focus on the following key areas: the evolving competitive environment, changes in corporate organization, the adoption of new technologies and shifts in labour use. (Abstract shortened by UMI.)
Ludick, Christopher Vernon. "Assessing the micro-economic impact of HIV/AIDS on a South African pharmaceutical manufacturer as well as evaluating their policy on HIV/AIDS." Thesis, Stellenbosch : Stellenbosch University, 2004. http://hdl.handle.net/10019.1/49857.
Повний текст джерелаENGLISH ABSTRACT: HIV infection has increased sharply in SA over the past decade, from almost zero to a level where between 4-6 million citizens are estimated to be HIV positive (i.e. around Il percent of the total population). Given the considerable lag and link between the HIV and AIDS epidemic, the mortality consequences of this exponential increase in HIV infection over the 1990s are more or less matter-of-fact over the coming decade; even drastic interventions can do little to avoid this reality, albeit possibly impactingfurther beyond. The health care industry, and more specifically the pharmaceutical industry, is the only industry that can have a direct impact on the outcome of the epidemic in terms of provision of antiretroviral drugs. More importantly, the decision by multinational companies to provide voluntary licensing to local SA pharmaceutical manufacturers for the manufacturing of generic ARVs has gone a long way into achieving the World Health Organisations' objective of providing an ARV cocktail for less than $1,00 per day. The mam aim of the study is to establish and study the micro-economic effect of HIV/AIDS on a South African pharmaceutical manufacturer and to evaluate their HIV/AIDS Policy with the framework of the mV/AIDS & SID Strategie Plan for South Africa 2000-2005. Both qualitative and quantitative methods were used to obtain data from various key informants, manufacturers and market survey companies. The analysis of quantitative data was done using Excel software and a descriptive analysis method was used to interpret the data. The key findings from the study are that Aspen Pharmacare will experience a 20,8 % HIV prevalence rate in 2005, which will progressively increase to a 25,6 % level in 2015. This prevalence level will be severely experienced in the skilled, semi-skilled and unskilled employment of the company during the 2010 period and will start to stabilise in the latter part of 2015. The AIDS prevalence in the company will increase from a 2,0 % level in 2005 to a 4,4 % level in 2015. This increase is largely due to the increase in the prevalence rates in the semi-skilled and unskilled employees. At a senior management level the forecasted number of employees that will have clinical AIDS after 2010 is between 6 and 8. This clearly indicates that mv/AIDS prevalence at this level is independent of race and is lifestyle dependent. If the company were to have the full responsibility for the provision of benefits, based on the current expected employee benefit structures, the direct cost to company would add 10 % to salary and wages by 2005 and around 20 % by 2010. Indirect costs to company, such as recruitment and training, increased labour turnover, lost skills and intellectual property, etc. are estimated to be 2,5 % by 2005 and 5 % by 2010. With the high HIV/AIDS prevalence rates, especially amongst the unemployed, companies will have to carry the costs of their mv/AIDS patients for longer and register then with Aid for AIDS when it becomes too costly. More importantly employers will have to investigate the cost implication of assisting employee dependents, as this will have a direct impact on the morale of the employees. Aspen Pharmacares' mv/AIDS Policy goes beyond the requirements of the mv/AIDS Strategic Plan for SA in terms of the legal and social requirements. The company also has a Corporate Social Investment division that assists many NGOs, clinics, hospitals and communities. Based on the intellectual property, the pharmaceutical competencies and the continuous dialogue that exists between the pharmaceutical industry and the department of health, the researcher concludes, that pharmaceutical companies have an advantage over nonpharmaceutical companies in dealing with the mv/AIDS issues. The paper concludes by suggesting recommendations that companies can adopt to ensure that their mv/AIDS policy can form a significant component of their skills retention strategy.
AFRIKAANSE OPSOMMING: MIV infeksie het skerp gestyg in SA oor die laaste dekade, vanaf amper geen tot 'n vlak waar tussen 4-6 miljoen inwoners beraam word om MIV positiefte wees (minstens 11% van die totale bevolking). Gegee die aansienlike vertraging en skakel tussen die MIV en VIGS epidemie, word die eksponensiële toename in die sterfte syfer as gevolg van MIV infeksies gedurende die jare negentig as vanselfsprekend aanvaar in die komende dekade. Selfs ingrypende veranderinge kan min doen om hierdie katastrofe te keer. Die gesondheidsorg industrie, en meer spesifiek die farmaseutiese industrie is die enigste industrie wat 'n direkte slag kan slaan om die uitkoms van die epidemie te beinvloed, in terme van voorsiening van antiretrovirale medisyne. Die besluit van die multinasionale maatskappye om vrywillige lisensiëring aan plaaslike farmaseutiese maatskappye te bied, vir die vervaardiging van generiese antiretrovirale medisyne, is een stap vorentoe om by die doelwit van die Wereld Gesondheidsorg Organisasie se doelwit van die voorsiening van 'n daaglikse toediening van antiretrovirale medisyne van minder as $1.00 per dag. Die primêre doelwit van hierdie projek is om te bepaal wat die mikro-ekonomiese effek van MIV/VIGS op 'n Suid Afriakaanse farmaseutiese vervaardiger is en hul MIV/VIGS beleid te evalueer binne die raamwerk van die MIV/VIGS en SOS Strategiese Plan vir SA 2000-2005. Beide kwalitatiewe en kwantitatiewe metodes is gebruik om data te verkry vanaf verskeie bronne, vervaardigers en marknavorsings maatskappye. Die kwantitatiewe inligting was geanaliseer deur gebruik te maak van "Excel" sagteware en 'n beskrywende analitiese metode was gebruik om die data te interpreteer. Die hoof bevindinge van die studie is dat Aspen Pharmacare 'n MIV infeksie vlak van 20.8 % in 2005 sal ondervind, wat progressief sal toeneem tot 25,6 % in 2015. Hierdie infeksie vlak sal in die geskoolde, semi-geskoolde en ongeskoolde arbeid die ergste voorkom gedurende die 2010 periode en sal dan stabiliseer in die latere gedeelte van 2015. Die VIGS infeksie vlak in die maatskappy sal toeneem vanaf 2,0 % in 2005 tot 'n 4,4 % in 2015. Hierdie toename kan toegeskryf word aan die toename in die infeksie vlakke van die semi-geskoolde and ongeskoolde arbeid. Op die senior bestuurs vlak word beraam dat tussen 6 en 8 werknemers VIGS onder lede sal hê na 2010. Hierdie beraming toon duidelik aan dat MIV/VIGS op hierdie vlak onafhankilik van kleurgroup is en direk leefstyl verwant is. Gebaseer op die huidige verwagte werknemer voordele struktuur, en die feit dat die maatskappy volle verantwoordelikheid sou aanvaar vir die voorsiening van voordele, word beraam dat die direkte koste as gevolg van MIV/VIGS 'n toename van 10 % in 2005 en 20 % in 2010 by salarisse en lone sal voeg. 'n Toename van 2,5 % in 2005 en 5 % in 2010 word beraam vir indirekte koste (werwing van personeel, opleiding, ens.)as gevolg van MIV/VIGS. Met die hoë MIV/VIGS infeksievlakke, veral onder werkloses, sal maatskappye die kostes vebonde aan hul MIV/VIGS werknemers vir langer moet verduur en dan later sulke werknemers registreer by "Aid for AIDS" indien dit onbekostigbaar word. Belangriker is die feit dat werknemers die koste implikasie bepaal in die verband, omdat dit 'n direkte invloed sal hê op werknemer selfvertroue. Aspen Pharmacare se MIV/VIGS beleid bied meer as die wettige en sosiale vereistes soos uiteengesit in die MIV/VIGS en SOS Strategiese Plan vir SA 2000-2005. Die maatskappy het ook 'n Korporatiewe Maatskaplike Beleggings afdeling wat 'n bydra lewer by NGOs, klinieke,hospitale en gemeenskappe. Gebaseer op die intelligensie eiendom, die farmaseutiese bekwaamheid en die aanhoudende gesprekvoering wat bestaan tussen die farmaseutiese bedryf en die department van gesondheid, oortuig die navorser dat farmaseutiese maatskappye 'n voordeel het bo nie-farmaseutiese maatskappye in die hantering van die MIV/VIGS strydvraag. Hierdie studie sluit af met aanbevelings wat maatskappye kan toepas om te verseker dat hul MIV/VIGS beleid 'n betekenisvolle komponent van hul bekwaanheids retensie strategie is.
易偉文 and Wai-man Winson Yick. "Franchise: a survival kit for the small real estate agency practice." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1998. http://hub.hku.hk/bib/B31256764.
Повний текст джерелаGumede, Halalisani. "The development of a putative microbial product for use in crop production." Thesis, Rhodes University, 2008. http://eprints.ru.ac.za/1352/.
Повний текст джерелаКниги з теми "Immunosuppressive agents Economic aspects"
Material markets: How economic agents are constructed. New York: Oxford University Press, 2008.
Знайти повний текст джерелаProvenzano, George. Economic considerations in regulating neurotoxic substances. [Washington, D.C.?: Office of Technology Assessment, 1989.
Знайти повний текст джерелаRibeiro, Gustavo Lins. Other globalizations: Alter-native transnational processes and agents. Brasília: Departamento de Antropologia, Universidade de Brasília, 2006.
Знайти повний текст джерелаTella, Rafael Di. Choosing agents and monitoring consumption: A note on wealth as a corruption-controlling device. Cambridge, Mass: National Bureau of Economic Research, 2007.
Знайти повний текст джерелаWeaver, David B. Not just surviving, but thriving: Identifying the strengths of highly successful American travel agencies. [Columbia, S.C.?]: University of South Carolina Press, 2006.
Знайти повний текст джерелаThirumurthy, Harsha. The economic impact of AIDS treatment: Labor supply in western Kenya. Cambridge, Mass: National Bureau of Economic Research, 2005.
Знайти повний текст джерелаCockburn, Iain. Hedonic analysis of arthritis drugs. Cambridge, MA: National Bureau of Economic Research, 1998.
Знайти повний текст джерелаStiernberg, John. Succeeding in music: A business handbook for performers, songwriters, agents, managers, & promoters / [John Stiernberg]. San Francisco: Backbeat Books, 2001.
Знайти повний текст джерелаVeldhuisen, D. R. van. Technical and economic aspects of measures to reduce water pollution from the textile finishing industry. Luxembourg: Office for Official Publications of the European Communities, 1994.
Знайти повний текст джерелаBall, Richard J. Michigan agriculture and its linkages to developing nations.: A guide for extension agents and other discussion leaders. East Lansing, Mich: Michigan Cooperative Extension Service, Michigan State University, 1988.
Знайти повний текст джерелаЧастини книг з теми "Immunosuppressive agents Economic aspects"
Bell, Clive, and T. N. Srinivasan. "Some Aspects of Linked Product and Credit Market Contracts Among Risk‐Neutral Agents." In The Economic Theory of Agrarian Institutions, 221–36. Oxford University Press, 1991. http://dx.doi.org/10.1093/0198287623.003.0011.
Повний текст джерелаRiddell, Anna, and Marta Gonzalez Sanz. "Infections in the Immunocompromised Host." In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0050.
Повний текст джерелаSingh, Danny. "The political, economic and cultural drivers of police corruption." In Investigating Corruption in the Afghan Police Force, 73–94. Policy Press, 2020. http://dx.doi.org/10.1332/policypress/9781447354666.003.0005.
Повний текст джерелаBalasko, Yves. "Goods and Prices." In General Equilibrium Theory of Value. Princeton University Press, 2011. http://dx.doi.org/10.23943/princeton/9780691146799.003.0001.
Повний текст джерелаRahman, Hakikur. "Open Innovation." In Advances in Human and Social Aspects of Technology, 273–307. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-5225-0556-3.ch012.
Повний текст джерелаAlves da Veiga, Pedro, Mirian Tavares, and Heitor Alvelos. "Toward a B-Society Model." In User Innovation and the Entrepreneurship Phenomenon in the Digital Economy, 194–216. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-2826-5.ch010.
Повний текст джерелаPoznyak, Sergiy, and Yurii Kolyada. "FORECASTING THE POTENTIAL OF THE ECONOMIC SYSTEM ON THE BASIS OF THE EXOGENIC GROWTH MODEL." In Integration of traditional and innovation processes of development of modern science. Publishing House “Baltija Publishing”, 2020. http://dx.doi.org/10.30525/978-9934-26-021-6-20.
Повний текст джерелаPaz-Gil, Iria, Alberto Prado Román, and Miguel Prado Román. "Is the COVID-19 Pandemic Shifting the Social-Business Paradigm?" In Advances in Human Resources Management and Organizational Development, 254–71. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-6713-5.ch012.
Повний текст джерелаRalha, Celia G., and Carolina G. Abreu. "Mase." In Advances in Computational Intelligence and Robotics, 106–27. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-1756-6.ch005.
Повний текст джерелаGómez-Ullate, Martín, Javier Barra Sanz, and Manuel Rodríguez Palacios. "Music and Musical Heritage as Factors for Rural Development." In Challenges and New Opportunities for Tourism in Inland Territories, 207–22. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-7339-6.ch012.
Повний текст джерелаТези доповідей конференцій з теми "Immunosuppressive agents Economic aspects"
Tepecik, Filiz. "Economic and Legal Aspects of Trafficking in Human Beings." In International Conference on Eurasian Economies. Eurasian Economists Association, 2013. http://dx.doi.org/10.36880/c04.00780.
Повний текст джерелаPrymek, M., A. Horak, and T. Sikora. "Smart power network reliability modelling using intelligent agents: Exploring economic aspects of the power distribution network reliability." In Expo on Emerging Technologies for a Smarter World (CEWIT 2011). IEEE, 2011. http://dx.doi.org/10.1109/cewit.2011.6135860.
Повний текст джерелаSushkov, N. "Reengineering of business processes of a trucking company." In International Conference "Computing for Physics and Technology - CPT2020". ANO «Scientific and Research Center for Information in Physics and Technique», 2020. http://dx.doi.org/10.30987/conferencearticle_5fd755bff31bf4.67804364.
Повний текст джерелаWidmer, L. K., M. Th Widmer, E. Zemp, F. Duckert, G. Marbet, H. E. Schmitt, E. Brandenberg, and R. Voëlin. "LONG-TERM MORBIDITY AFTER DEEP VEIN THROMBOSIS (DVT)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642969.
Повний текст джерела